Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
